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Infective endocarditis (IE) remains a challenging clinical 
entity.[1] It has a relatively low incidence, the clinical 
presentation varies widely and the offending organisms 
cover a large spectrum of microbiological species. It is 
therefore not uncommon that the diag nosis is delayed.
Despite advances in its management, it remains a condition 
with a high mortality and significant morbidity. Paucity of data, 
particularly in Africa where rheumatic valvular heart disease is still 
highly prevalent, makes decisions regarding the optimal treatment 
of this disease very difficult. To complicate matters, there has been 
considerable controversy surrounding prevention of the disease.
The objective of this article is to inform the clinician on the 
current state of knowledge of IE in order to provide a practical 
approach to the patient with suspected IE.
Bacteriology
Viridans streptococci account for 50 - 70% of native valve IE. 
Staphylococcus aureus is responsible for a further 25%. Various 
bacilli, the HACEK group of organisms (Haemophilus, Actinobacillus, 
Cardiobacterium, Eikenella and Kingella spp.) and fungi are rare.
The offending organisms in prosthetic valve endocarditis are 
frequently Staphylococcus epidermidis or S. aureus.
Prevention
Previously, antibiotic prophylaxis was administered widely to patients 
with various predisposing cardiac conditions. In 2002 the indications 
for antibiotic prophylaxis were restricted to a much smaller population 
of patients with cardiac pathology,[2] for various reasons:
• Bacteraemia occurs more frequently during routine activities 
(e.g. toothbrushing) and the risk of endocarditis may be related 
to generally poor dental health rather than occasional high-grade 
bacteraemia following a dental procedure.
• There is poor correlation between invasive dental procedures and IE.
• The estimated risk of IE following a dental procedure is very low.
• Antibiotic prophylaxis carries a small but definite risk of anaphy-
laxis/severe allergic reaction.
• Prophylactic antibiotic use may contribute to increased resistant 
bacteria.
• There are no randomised controlled trials that have investigated 
whether antibiotic prophylaxis does in fact reduce the incidence 
of IE.
In a recent analysis in the UK, the incidence of IE increased 
significantly after introduction of the restricted antibiotic prophylaxis 
guidelines. It is not entirely certain what conclusions can be drawn 
from this observational data, where confounding factors cannot 
be excluded. The finding has not been confirmed in various 
observational studies in other countries.
The current European Society of Cardiology (ESC) guidelines still 
recommend that antibiotic prophylaxis should be considered for:
• Patients with a prosthetic valve or where prosthetic material was 
used for surgical repair of a valve.
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Although infective endocarditis (IE) is relatively uncommon, it remains an important clinical entity with a high in-hospital and 1-year 
mortality. It is most commonly caused by viridans streptococci. Staphylococcus aureus is responsible for a malignant course of IE and 
often requires early surgery to eradicate. Other rarer causes are various bacilli, including the HACEK (Haemophilus, Actinobacillus, 
Cardiobacterium, Eikenella and Kingella spp.) group of organisms and fungi. The clinical presentation varies. Patients may present with 
a nonspecific illness, valve dysfunction, heart failure (HF) and symptoms due to peripheral embolisation. The diagnosis is traditionally 
based on the modified Duke criteria and rests mainly on clinical features and to a lesser extent on certain laboratory findings, 
microbiological assessment and cardiovascular imaging. Identification of the offending micro-organism is not only important from a 
diagnostic point of view, but also makes targeted antibiotic treatment possible and provides useful prognostic information. A significant 
proportion of microbiological cultures are negative, frequently owing to the administration of antibiotics prior to appropriate culture. 
Blood-culture-negative IE poses significant diagnostic and treatment challenges. The course of the disease is frequently complicated, and 
sequelae include HF, local intracardiac extension of infection (abscess, fistula, pseudoaneurysm), stroke and intracranial haemorrhage 
due to septic emboli or mycotic aneurysm formation as well as renal injury. Management includes prolonged intravenous antibiotics and 
consideration for early surgery with removal of infective tissue and valve replacement in patients who have poor prognostic features or 
complications. Antibiotic administration for at-risk patients to prevent bacteraemia during specific procedures (particularly dental) is 
recommended to prevent IE. The patient population who would benefit from antibiotic prophylaxis has become increasingly restricted, 
and guidelines recommend prophylaxis only for patients with cyanotic congenital heart disease, prosthetic heart valves and a previous 
episode of IE. The management of a patient with IE is challenging and often requires multidisciplinary input from an IE heart team, 
which includes cardiologists. 
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• Patients with a previous episode of IE.
• Any type of cyanotic congenital heart disease.
• Any coronary heart disease repaired with prosthetic material up to 
6 months after the procedure or lifelong if there is residual shunt/
valvular regurgitation.[3]
Furthermore, the use of antibiotic prophylaxis is limited to dental 
procedures requiring manipulation of the gingival/periapical tooth 
region or perforation of the oral mucosa. Antibiotic prophylaxis is 
not recommended for less-invasive procedures such as bronchoscopy, 
gastroscopy, colonoscopy, cystoscopy or skin/soft-tissue procedures. 
This also includes caesarean sections and vaginal delivery. Respiratory, 
gastrointestinal tract or genitourinary procedures where antibiotic 
prophylaxis is given to prevent wound infection or sepsis should 
receive the appropriate antibiotic.
The recommended regimen for patients in whom antibiotic 
prophylaxis is indicated is amoxicillin 2 g orally or intravenously (IV) 
30 - 60 minutes prior to the procedure. Patients with a penicillin allergy 
should receive clindamycin 600 mg orally or IV.
Lastly, the following general measures to reduce bacteraemia are 
felt to be very important:
• Strict dental and cutaneous hygiene.
• Disinfection of any wounds.
• Eradication of chronic bacterial carriage: skin/nasal/urine.
• Aggressive therapy of any bacterial infection.
• Strict infection control measures for any procedure.
There have been case reports of IE after body piercing or tattooing; 
therefore, these should be strongly discouraged in at-risk individuals.
A final comment must be made surrounding so-called healthcare-
associated IE. This accounts for up to 30% of all cases of IE. To 
prevent this, the following points are important:
• The often unnecessary use of IV catheters should be limited. 
• A strict aseptic technique should be followed, particularly when 
placing central catheters. 
• Catheters should be changed routinely every 3 - 4 days.
Diagnosis
The modified Duke criteria provide a formal framework for the 
diagnosis of IE and are shown in Tables 1 and 2.[4] An important caveat is 
that the Duke criteria have a sensitivity of 80% for the diagnosis of IE.[5] It 
is therefore possible to miss IE if one applies the Duke criteria too strictly.
The diagnosis is based on four distinct legs:
• Clinical features.
• Laboratory findings.
• Imaging.
• Microbiological tests.
Table 1. Definition of IE according to modified Duke criteria
Definite IE
Pathological criteria
 Micro-organism demonstrated by culture or histological 
examination of a vegetation, a vegetation that has embolised, 
or an intracardiac abscess specimen, or
 Pathological lesions vegetation or intracardiac abscess confirmed 
by histological examination showing active endocarditis
Clinical criteria
2 major criteria, or
1 major criterion and 3 minor criteria, or
5 minor criteria
Possible IE
1 major criterion and 1 minor criterion, or
3 minor criteria
Rejected IE
Firm alternative diagnosis, or
Resolution of symptoms suggesting IE after antibiotic therapy for 
<4 days, or
No pathological evidence of IE at surgery or autopsy, with antibiotic 
therapy for <4 days, or
Does not meet criteria for possible IE, as above
Table 2. Definition of terms used in the Duke criteria
Major criteria
Blood culture positive for IE
 Typical micro-organism consistent with IE from two separate 
blood cultures
 Viridians streptococci, Streptococcus gallolyticus, HACEK 
group, S. aureus, or
 Community-acquired enterococci, in the absence of a primary 
focus, or
 Micro-organisms consistent with IE from persistently positive 
blood cultures defined as follows:
 >2 positive blood cultures of blood samples drawn >12 hours 
apart, or
 All of 3 or a majority of >4 separate blood cultures (with first 
and last sample drawn >1 hour apart), or
 Single positive blood culture for Coxiella burnetti or 
IgG titre >1:800
Imaging positive for IE
Echocardiogram positive for IE
Vegetation, or
Abscess, pseudoaneurysm, intracardiac fistula, or
Valvular perforation or aneurysm, or
New partial dehiscence of prosthetic valve
Definite paravalvular lesions on cardiac CT
 Abnormal activity around the site of prosthetic valve 
implantation detected by 18F-FDG PET/CT (only if prosthesis 
was implanted for >3 months) or radio-labelled leukocytes SPECT
Minor criteria
Predisposition, such as predisposing heart condition or IV drug use
Fever defined as temperature >38°C
Vascular phenomena (including those detected by imaging only)
Major arterial emboli
Septic pulmonary infarcts
Infectious aneurysm
Intracranial haemorrhage
Conjunctival haemorrhages
Janeway’s lesions
Immunological phenomena
Glomerulonephritis
Osler’s nodes
Roth’s spots
Rheumatoid factor
Microbiological evidence
 Positive blood culture but does not meet major criteria for 
blood cultures as noted above, or
 Serological evidence of active infection with organism consistent with IE
18F-FDG PET/CT = fluorine-18 fluorodeoxyglucose positron emission tomography/
computed tomography; SPECT = single-photon emission computed tomography.
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Clinical features
IE usually has an acute onset, and it often causes 
multisystem disease with skin mani festations 
that can imitate a number of diseases.[6] In a 
primary care setting it is important to have a 
high index of suspicion, and the clinical history 
of a patient with unexplained high fever should 
always include asking about possible risk factors 
such as pre vious cardiac valvular disease, IV 
drug use, the presence of prosthetic devices 
(prosthetic valves, orthopaedic hardware), as 
well as cardiac implantable electronic devices 
such as pacemakers, which can be possible 
sources of infection.
The clinical picture of IE varies from 
nonspecific symptoms to symptoms sugges-
tive of pre-existing cardiac valvular disease, 
as well as embolic phenomena. Nonspecific 
symptoms include a high fever (in about 
80 - 90% of cases), headache, anorexia, 
myal gia, night sweats and joint pains.[7,8] The 
patient often presents acutely, with no prior 
history of valvular disease or existing cardiac 
murmurs. 
Patients with pre-existing valve lesions 
and congenital heart disease usually present 
with the subacute form of the disease. There 
is an overlap of symptoms with those found 
in acute cases, because the clinical picture 
is influenced by the source or site of the 
infection, as well as the organism involved. 
About 99% of these patients will have a 
cardiac murmur but only 10% of these 
patients have a change in the characteristics 
of the murmur.[9] Patients who have left-
sided valvular insufficiency may present 
with an acute onset of congestive cardiac 
failure. Splenomegaly is found in about 11% 
of patients with long-standing disease, but 
clubbing of fingers and toes is rare. 
The classic signs of IE are summarised in 
Table 3. 
Patients who have embolic complications 
can present with neurological outcomes 
(40% of cases), which include hemiparesis, 
paralysis and aphasia. In 50% of patients 
who present with cerebral emboli as the 
first manifestation of IE, there is a 2 - 
4 times increased mortality rate. It is 
therefore impor tant to enquire about 
the previously men tioned risk factors as 
possible sources of infection, especially 
in a young person who presents with 
stroke symptoms. Other manifestations 
include glomerulonephritis and renal 
failure. Systemic septic emboli (S. aureus 
infection) can result in abscess formation 
in almost any organ, including the heart, 
brain and kidneys.
IV drug users (IVDUs) are susceptible to 
tricuspid IE. These patients have pulmonary 
symptoms, in addition to symptoms such 
as high fever and petechiae. IVDUs with 
concurrent HIV infection are at increased 
risk of tricuspid valve endocarditis. Patients 
with advanced stages of HIV disease have a 
greater mortality risk of IE.[10]
Laboratory findings
None of the various laboratory investigations 
that are performed are diagnostic, and 
generally have poor positive predictive 
values. The tests are at most supportive 
in the diagnosis of IE. A raised white cell 
count or other marker of sepsis such as 
a raised erythrocyte sedimentation rate, 
C-reactive protein or procalcitonin may be 
found. Anaemia of chronic disease can be 
present. Patients may have low complement 
levels or elevated rheumatoid factor. An 
ele vated creatinine may be due to acute 
tubular necrosis, immune-complex mediated 
nephritis or renal emboli.
Imaging
Echocardiography
Echocardiography remains one of the most 
useful investigations in the evaluation 
of some one with suspected IE.[11] If the 
transthoracic echo cardiogram is negative, 
one should proceed to trans oesophageal 
echocardiography to obtain the necessary 
image quality to look for small vegetations 
or early intracardiac complications (e.g. 
perivalvular abscesses).[12] Transoesophageal 
echocardiography must also be performed in 
patients with suspected prosthetic valve endo-
carditis. The resolution of a transthoracic 
echo cardiogram is not adequate in this 
setting. Patients with S. aureus bacteraemia 
often have underlying IE with a very poor 
prognosis, and an echocardiogram is 
recommended in this setting to look for 
IE.[13] It needs to be emphasised that a normal 
echocardiogram does not rule out IE and if 
the clinical suspicion remains high, the study 
should be repeated 5 days later.
Computed tomography scanning
Multislice computed tomography (CT) may 
be helpful to detect the following:
• CT coronary angiography is helpful in 
patients in whom a preoperative angiogram 
is indicated. The risks of invasive angiography 
including potential dislodgement of vege-
tation are thus avoided.
• Multislice CT of the lungs, spleen or brain 
can detect embolic lesions, which can help 
to  confirm the diagnosis of IE.
• Cardiac CT can detect intracardiac/peri-
valvular abscesses and fistulae.
Magnetic resonance imaging
This may help in detecting cerebral lesions. 
Cardiovascular magnetic resonance may 
be helpful in identifying vegetations, myo-
cardial abscesses and other associated 
comp lications. 
Table 3. Clinical signs of IE
Clinical sign Occurrence, % Description
Petechiae Common, 
nonspecific
Common, nonspecific and found on 
extremities, mucosa and palate
Splinter haemorrhages 8 Dark, linear lesions in nail beds 
Osler’s nodes Tender, papulopustules on distal pads of 
digits
Roth’s spots 5 Retinal haemorrhages with small, clear 
centres
Janeway’s lesions 5 Painless erythematous macules on palms of 
hands and soles of feet
Conjunctival haemorrhages 5 Bright red/dark red patch on the sclera 
Haematuria 25 Blood in the urine
Table 4. Empirical therapy of IE
Condition Antibiotics Dose Duration (weeks)
Native valve IE Penicillin 6 mU given 6-hourly IV 4
Gentamicin 3 mg/kg/day given 12-hourly IV 2
Prosthetic valve IE Vancomycin 30 mg/kg/day given 12-hourly IV 6
Rifampicin 15 mg/kg/day given 12-hourly po 6
Gentamicin 3 mg/kg/day given 12-hourly IV 2
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Nuclear imaging
In centres with the necessary exper tise and 
equipment, fluorine-18 fluoro deoxyglucose 
positron emission tomo graphy/CT (18F-FDG 
PET/CT) can diagnose septic foci.
Microbiological tests
Blood cultures are critical in the diagnosis of 
IE. It is recommended that three sets are taken 
at least 30 minutes apart. Peripheral samples 
are preferred. Blood cultures do not need to 
be timed with fever spikes, as bacteraemia 
in IE is very constant. Similarly, a single 
positive blood culture should be interpreted 
carefully, as usually in IE all blood cultures 
will be positive. Positive blood cultures allow 
for identification of the causative organism as 
well as antibiotic susceptibility testing.
Unfortunately, in about one-third of 
cases blood cultures are negative. This 
frequently results in diagnostic dilemmas 
and considerable challenge in terms of 
therapy. By far the most common cause 
is prior antibiotic administration without 
appropriate blood cultures being taken at the 
time. In these cases it may be useful (if the 
clinical status of the patient allows) to stop 
the antibiotics and repeat blood cultures.
Another cause of blood-culture-negative 
IE is unusual organisms such as fungi 
and certain intracellular bacteria, which 
require specific growth media. Serology 
and polymerase chain reaction (PCR) for 
specific organisms (Coxiella, Bartonella and 
Brucella) may be helpful in these cases.[14]
Lastly, microbiological examination of 
resected tissue during surgery can be extre-
mely helpful. All tissue excised during surgery 
should be sent for appropriate micro biological 
and histological investigation.
Complications
Not all the potential complications of IE are 
discussed here, but some of the more commonly 
occurring problems deserve special mention. 
Apart from heart failure, IE can manifest comp-
lications affecting the central nervous system, 
spleen, kidneys as well as blood vessels with the 
formation of mycotic aneurysms.
Neurological
About 20% of patients develop symptomatic 
neurological complications. These are usual-
ly due to septic emboli and may be the 
first manifestation of IE. The usual clinical 
presentation is with focal neurological 
signs due to an ischaemic stroke but more 
severe complications such as haemorrhage, 
meningitis and abscess formation can occur. 
Cardiac surgery to prevent further embolism 
should be considered early in patients with 
neurological complications.
Spleen
Splenic abscesses or rupture present with 
abdominal pain and often a failure of anti-
biotic therapy. Although this complication 
is rare, it is important to recognise as these 
patients may require splenectomy to cure 
their infection; however, small abscesses may 
still respond to antibiotics alone.
Heart block
This is a rare complication but usually indi-
cates perivalvular spread of the infection and is 
therefore often an indication for surgery.
Kidney
Up to 30% of patients can develop acute renal 
failure. The following aetiologies should be 
considered:
• Acute tubular necrosis due to sepsis or 
haemodynamic compromise.
• Immune complex-mediated glomerulo-
nephritis.
• Renal infarction due to emboli.
• Drug toxicity or drug-induced nephritis.
Treatment
The therapy of IE comprises appropriate 
antibiotic therapy, cardiac surgery to resect 
infected cardiac tissue (usually with valve 
replace ment) and the treatment of compli-
cations.
Antibiotic therapy
Specific antibiotic therapy should be guided 
by the identification of the organism and 
results of antibiotic susceptibility testing. 
Tables 4 - 9 outline the empirical treatment 
of patients with IE (before blood culture 
results are available) as well as the antibiotic 
regimen for the most common organisms 
once they have been identified by cultures.[15] It 
is strongly recommended to discuss the specific 
treatment regimen with a microbiologist/
infectious disease specialist.
Surgery
Surgery is indicated broadly for three reasons: 
the development of heart failure, inadequate 
response to antibiotic therapy and a reduction 
in the risk of septic embolism.
• Heart failure
Heart failure is usually on the basis of severe 
mitral or aortic regurgitation. Patients who do 
not respond to medical heart failure therapy 
should undergo surgery within 24 hours. 
Table 5. Therapy for streptococcal IE (native valve)
Condition Antibiotics Dose Duration (weeks)
Viridans streptococci 
susceptible to penicillin
Penicillin 6 mU given 6-hourly IV 4
Viridans streptococci moderately 
susceptible to penicillin
Penicillin 6 mU given 6-hourly IV 4
Gentamicin 3 mg/kg/day given 
12-hourly IV
2
Viridans streptococci 
moderately resistant to 
penicillin
Penicillin 6 mU given 6-hourly IV 4
Gentamicin 3 mg/kg/day given 
12-hourly IV
4
Enterococci susceptible to 
penicillin
Penicillin 6 mU given 6-hourly IV 4
Gentamicin 3 mg/kg/day given 
12-hourly IV
4
Abiotrophia/Granulicatella Penicillin 6 mU given 6-hourly IV 4
Gentamicin 3 mg/kg/day given 
12-hourly IV
4
Viridans streptococci fully 
resistant to penicillin
Vancomycin 30 mg/kg/day given 
12-hourly IV
6
Gentamicin 3 mg/kg/day given 
12-hourly IV
6
Enterococci resistant to 
penicillin
Vancomycin 30 mg/kg/day given 
12-hourly IV
6
Gentamicin 3 mg/kg/day given 
12-hourly IV
6
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Patients who respond to heart failure therapy should undergo surgery 
within 7 days. Patients who are left with valve lesions with no evidence 
of heart failure should be followed up and then operated on electively.
• Inadequate response to antibiotic therapy 
This usually manifests as either persisting fever or persistently positive 
blood cultures for >7 days after initiation of appropriate antibiotic 
therapy. Another manifestation of uncontrolled infection is the 
development of local cardiac complications such as abscesses, false 
aneurysm, fistulae and vegetations that are enlarging. In these cases 
surgery within 7 days is advised to remove infective tissue and treat 
local complications. Some infections are caused by organisms (e.g. 
fungi or resistant organisms) that have a high likelihood of not being 
adequately treated with antibiotic therapy alone. In these patients, early 
surgery with removal of infective tissue should strongly be considered.
• Reduction in embolism risk
Patients who have vegetations >10 mm, in particular if they have had 
a previous embolic episode or other poor prognostic factors (e.g. 
heart failure), should be considered for early surgery.[16]
Cardiac device-related IE
Patients who develop IE with involvement of a pacemaker or 
ICD deserve a special mention because mortality in this setting is 
particularly high and treatment is often very difficult. Apart from 
following the principles outlined above to make the diagnosis, it 
needs to be emphasised that the treatment of IE in this setting should 
not involve  prolonged antibiotic therapy only, but also complete 
removal of all device-associated hardware (pacemaker and leads). If 
this is not performed, recurrence frequently occurs.
Prognosis
Between 15% and 30% of patients will die from IE in hospital. Table 
10 outlines the predictors of a poor outcome for these patients. 
Patients with heart failure, periannular complications or S. aureus 
infections are at highest risk of in-hospital death or need for surgery. 
The risk is cumulative and is 79% if a patient has all three of the 
aforementioned risk factors.[17,18]
Conclusion
IE is a serious condition with a high mortality. It is difficult 
to diagnose and treat, and optimal management often requires 
input from multiple medical as well as surgical disciplines. Early 
surgery is frequently beneficial in patients with IE, and access 
to a good cardiac surgery service is therefore of paramount 
importance. As a final point we recommend that all patients with 
suspected IE are referred to a specialist centre for investigation 
and management.
Table 6. Therapy for streptococcal IE (prosthetic valve)
Condition Antibiotics Dose Duration (weeks)
Viridans streptococci susceptible to penicillin Penicillin 6 mU given 6-hourly IV 6
Gentamicin 3 mg/kg/day given 12-hourly IV 2
Viridans streptococci moderately susceptible to penicillin Penicillin 6 mU given 6-hourly IV 6
Gentamicin 3 mg/kg/day given 12-hourly IV 6
Viridans streptococci moderately resistant to penicillin Penicillin 6 mU given 6-hourly IV 6
Gentamicin 3 mg/kg/day given 12-hourly IV 6
Enterococci susceptible to penicillin Penicillin 6 mU given 6-hourly IV 6
Gentamicin 3 mg/kg/day given 12-hourly IV 6
Abiotrophia/Granulicatella Penicillin 6 mU given 6-hourly IV 6
Gentamicin 3 mg/kg/day given 12-hourly IV 6
Viridans streptococci fully resistant to penicillin Vancomycin 30 mg/kg/day given 12-hourly IV 6
Gentamicin 3 mg/kg/day given 12-hourly IV 6
Enterococci resistant to penicillin Vancomycin 30 mg/kg/day given 12-hourly IV 6
Gentamicin 3 mg/kg/day given 12-hourly IV 6
Table 7. Therapy for staphylococcal IE
Condition Antibiotics Dose Duration (weeks)
Native valve: cloxacillin/methicillin sensitive Cloxacillin 2 g given 6-hourly IV 4 - 6
Native valve: cloxacillin/methicillin resistant Vancomycin 30 mg/kg/day given 12-hourly IV 4 - 6
Rifampicin 15 mg/kg/day given 12-hourly po 4 - 6
Prosthetic valve: cloxacillin/methicillin sensitive Cloxacillin 2 g given 6-hourly IV 6 - 8
Rifampicin 15 mg/kg/day given 12-hourly po 6 - 8
Gentamicin 3 mg/kg/day given 12-hourly IV 2
Prosthetic valve: cloxacillin/methicillin resistant Vancomycin 30 mg/kg/day given 12-hourly IV 6 - 8
Rifampicin 15 mg/kg/day given 12-hourly po 6 - 8
Gentamicin 3 mg/kg/day given 12-hourly IV 2
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Table 10. Predictors of poor outcome in patients with IE[3]
Patient factors
Older age
Prosthetic valve IE
Diabetes mellitus
Comorbidity (e.g. frailty, immunosuppression, renal/pulmonary disease)
Complications
Heart failure
Renal failure
Greater than moderate area of ischaemic stroke
Brain haemorrhage
Septic shock
Micro-organism
S. aureus
Fungi
Non-HACEK Gram-negative bacilli
Echocardiographic findings
Periannular complications
Severe left-sided valve regurgitation
Low left-ventricular ejection fraction
Pulmonary hypertension
Large vegetations
Severe prosthetic valve dysfunction
Premature mitral valve closure and other signs of elevated diastolic pressures
